NCT04663737View on ClinicalTrials.gov

Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2020

Primary Completion Date

August 16, 2021

Study Completion Date

October 4, 2021

Conditions

Covid19

Interventions

DRUG

Silmitasertib

Capsules

DRUG

SOC

Some therapeutics for COVID-19 are available through EUA. SOC treatment availability is expected to change during the course of this trial.

Trial Locations (1)

30501

Center for Advanced Research and Education, Gainesville

All Listed Sponsors

lead

Senhwa Biosciences, Inc.

INDUSTRY

NCT04663737 - Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19 | Biotech Hunter | Biotech Hunter